^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CAP-100: First-in-class antibody for CCR7+ hematological malignancies.

Published date:
05/26/2019
Excerpt:
...CAP-100 was shown to inhibit entry of CCR7-expressing cells to LNs...CAP-100 also abrogated survival elicited by CCR7 in CLL, and showed potent cell killing activity against CLL or CCR7+ T-lymphomas cells. 
DOI:
10.1200/JCO.2019.37.15_suppl.e19008